LGND
Ligand Pharmaceuticals Incorporated
298.40$
+0.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| -25.5% | -19.0% | -43.5% | 7.6% | 3.4% | 18.3% | 21.0% | 22.4% | 24.3% | 22.6% | 16.1% | 455.5% | 152.7% | 39.1% | 27.4% | 16.3% | 11.5% | 11.7% | 14.2% | 8.1% | 5.1% | 3.8% | 2.5% | 9.4% | 18.6% | 25.7% | 26.9% | 26.7% | 6.6% | 2.5% | |
| 125.5% | 119.0% | 143.5% | 92.4% | 96.6% | 81.7% | 79.0% | 77.6% | 75.7% | 77.4% | 83.9% | 100.0% | 100.0% | 60.9% | 100.0% | 83.7% | 88.5% | 88.3% | 85.8% | 91.9% | 94.9% | 96.2% | 97.5% | 90.6% | 81.4% | 74.3% | 73.1% | 73.3% | 93.4% | 97.5% | |
| 161.7% | 140.0% | 399.4% | 145.2% | 106.6% | 66.9% | 60.9% | 48.0% | 39.9% | 31.8% | 29.7% | 346.1% | 112.6% | 102.4% | 93.8% | 34.3% | 34.4% | 18.9% | 18.8% | 18.6% | 19.5% | 19.1% | 11.1% | 46.5% | 24.8% | 13.3% | 18.4% | 18.7% | 12.8% | 30.3% | |
| 27.7% | 19.5% | 93.8% | 66.7% | 70.9% | 45.1% | 43.1% | 43.2% | 58.6% | 60.7% | 176.1% | 235.8% | 87.1% | 78.2% | 126.3% | 49.9% | 51.3% | 36.7% | 35.0% | 33.9% | 24.4% | 20.3% | 15.0% | 34.8% | 36.7% | 19.4% | 35.7% | 40.2% | 47.1% | 34.5% | |
| 214.9% | 178.5% | 536.7% | 230.1% | 192.0% | 112.0% | 104.0% | 91.2% | 98.5% | 92.4% | 203.7% | 566.7% | 192.5% | 180.6% | 220.0% | 84.1% | 85.7% | 55.7% | 53.8% | 52.5% | 53.7% | 48.0% | 32.4% | -580.4% | 58.5% | 31.3% | 71.5% | 64.2% | 106.9% | 79.9% | |
| -89.4% | -59.6% | -393.2% | -137.7% | -95.4% | -30.3% | -25.0% | -13.6% | -22.9% | -15.0% | -119.7% | -466.7% | -356.1% | -25.6% | -124.5% | -2.3% | 1.8% | 30.5% | 30.4% | 38.0% | 40.3% | 48.2% | 65.1% | 671.0% | 22.9% | 43.0% | 1.5% | 9.1% | -13.5% | 17.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 6.5% | 7.8% | 0.0% | 6.3% | 7.5% | 5.7% | 0.7% | 0.7% | 0.2% | 8.3% | 10.5% | 4.2% | 7.5% | 16.4% | 11.2% | 8.1% | 19.2% | 29.7% | 16.8% | 8.1% | 0.9% | 0.5% | 1.8% | 1.8% | |
| -79.3% | -178.1% | -636.2% | -151.6% | -97.1% | -41.3% | -33.7% | -26.5% | -27.5% | 20.6% | -123.6% | -414.6% | -357.0% | -25.4% | -65.4% | -9.8% | -12.3% | 18.8% | 17.5% | 49.1% | 7.3% | 40.6% | 68.9% | 662.3% | 0.8% | 29.9% | 18.4% | 48.5% | 1.5% | 59.3% | |
| 12.0% | 134.2% | 272.9% | 45.0% | 55.1% | 26.0% | 8.7% | 13.0% | 0.1% | 0.0% | -27.3% | -145.0% | -0.2% | -20.3% | -11.1% | -43.6% | -3.8% | 0.8% | 0.6% | -305.4% | 9.5% | 31.7% | 11.9% | 139.1% | -3.2% | -1.7% | 21.0% | 7.5% | 3.9% | 12.9% | |
| -101.4% | -193.8% | -666.1% | -182.6% | -150.4% | -56.3% | -33.7% | -26.5% | -27.6% | -20.6% | -22.5% | 2,184.6% | -359.2% | -5.0% | -53.2% | 33.9% | -1.7% | 23.3% | 18.6% | 357.8% | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% | |
| -63.9% | -40.6% | -367.8% | -132.5% | -80.3% | -21.7% | -36.4% | -42.3% | -13.5% | -15.0% | -43.9% | -388.6% | -352.4% | -16.6% | -55.8% | 5.8% | 12.6% | 42.1% | 36.2% | 41.7% | 50.6% | 57.5% | 94.8% | 728.4% | 34.6% | 59.1% | 41.4% | 76.8% | 24.4% | 71.9% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.